Man Group’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-503,120
| Closed | -$24.5M | – | 2351 |
|
|
2025
Q3 | $24.5M | Buy |
503,120
+341,300
| +211% | +$21.1M | 0.04% | 443 |
|
|
2025
Q2 | $12.1M | Buy |
+161,820
| New | +$10.7M | 0.02% | 703 |
|
|
2025
Q1 | – | Sell |
-3,098
| Closed | -$242K | – | 2261 |
|
|
2024
Q4 | $242K | Sell |
3,098
-21,511
| -87% | -$1.73M | ﹤0.01% | 1836 |
|
|
2024
Q3 | $1.98M | Buy |
24,609
+4,669
| +23% | +$377K | 0.01% | 1315 |
|
|
2024
Q2 | $1.65M | Sell |
19,940
-52,723
| -73% | -$4.64M | ﹤0.01% | 1398 |
|
|
2024
Q1 | $6.2M | Buy |
72,663
+35,034
| +93% | +$2.75M | 0.02% | 904 |
|
|
2023
Q4 | $3.22M | Buy |
+37,629
| New | +$3.25M | 0.01% | 1124 |
|
|
2023
Q3 | – | Sell |
-92,157
| Closed | -$8.23M | – | 804 |
|
|
2023
Q2 | $7.85M | Buy |
+92,157
| New | +$7.79M | 0.02% | 712 |
|
|
2023
Q1 | – | Sell |
-71,356
| Closed | -$5.78M | – | 785 |
|
|
2022
Q4 | $5.61M | Sell |
71,356
-2,203
| -3% | -$177K | 0.02% | 786 |
|
|
2022
Q3 | $5.45M | Buy |
+73,559
| New | +$5.28M | 0.03% | 705 |
|
|
2022
Q2 | – | Sell |
-109,035
| Closed | -$6.45M | – | 663 |
|
|
2022
Q1 | $6.89M | Sell |
109,035
-355
| -0.3% | -$19.3K | 0.02% | 759 |
|
|
2021
Q4 | $5.8M | Buy |
109,390
+1,193
| +1% | +$72.7K | 0.02% | 822 |
|
|
2021
Q3 | $7.64M | Buy |
108,197
+2,283
| +2% | +$144K | 0.03% | 673 |
|
|
2021
Q2 | $7.06M | Buy |
105,914
+81,042
| +326% | +$5.73M | 0.02% | 733 |
|
|
2021
Q1 | $2.76M | Buy |
24,872
+2,442
| +11% | +$302K | 0.01% | 983 |
|
|
2020
Q4 | $2.66M | Sell |
22,430
-52,295
| -70% | -$5.63M | 0.01% | 1092 |
|
|
2020
Q3 | $6.52M | Sell |
74,725
-56,646
| -43% | -$4.95M | 0.03% | 677 |
|
|
2020
Q2 | $11.8M | Buy |
131,371
+49,160
| +60% | +$4.97M | 0.06% | 308 |
|
|
2020
Q1 | $8.19M | Sell |
82,211
-475
| -0.6% | -$51.5K | 0.05% | 352 |
|
|
2019
Q4 | $9.5M | Sell |
82,686
-94,353
| -53% | -$11.4M | 0.03% | 713 |
|
|
2019
Q3 | $22.3M | Buy |
177,039
+5,846
| +3% | +$742K | 0.08% | 289 |
|
|
2019
Q2 | $20.6M | Sell |
171,193
-9,820
| -5% | -$966K | 0.07% | 335 |
|
|
2019
Q1 | $15.8M | Sell |
181,013
-41,443
| -19% | -$3.77M | 0.06% | 388 |
|
|
2018
Q4 | $22.3M | Sell |
222,456
-480,664
| -68% | -$50.5M | 0.1% | 226 |
|
|
2018
Q3 | $80.6M | Buy |
703,120
+90,823
| +15% | +$9.4M | 0.29% | 55 |
|
|
2018
Q2 | $54.9M | Buy |
612,297
+481,439
| +368% | +$40.7M | 0.23% | 78 |
|
|
2018
Q1 | $9.57M | Buy |
+130,858
| New | +$8.98M | 0.04% | 518 |
|
Other funds holding HAE
Man Group's HAE Position: Q4 2025 in Review
Man Group sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 503,120 shares — an estimated $24.5M sold.
Man Group first reported a position in HAE in Q1 2018 and held it in 27 quarters. The position peaked at $80.6M in Q3 2018. 329 funds tracked by Wall St. Rank hold HAE as of Q4 2025.
- Man Group reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
- Man Group sold 503,120 Haemonetics shares in Q4 2025, an estimated $24.5M.
- Man Group first reported a position in Haemonetics in Q1 2018 and held it in 27 quarters.
- Man Group's Haemonetics position peaked at $80.6M in Q3 2018.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.
Based on Man Group's 13F filing for Q4 2025, filed 17 Feb 2026.